BELux Children OutcoME During A(@)Dulthood With GHD

Launched by CLINIQUES UNIVERSITAIRES SAINT-LUC- UNIVERSITÉ CATHOLIQUE DE LOUVAIN · Nov 15, 2024

Keywords

ClinConnect Summary

The BELux Children OutcoME During A(@)Dulthood With GHD trial is studying the long-term effects of a treatment called recombinant human growth hormone (rhGH) on individuals who were diagnosed with growth hormone deficiency (GHD) during childhood. The main goal of the study is to find out how many of these individuals continue to receive regular medical check-ups and whether they are still using rhGH therapy as adults. Researchers will also look into other health factors, such as lifestyle, quality of life, and any additional health problems that may have developed as they grew older.

To be eligible for the trial, participants need to be at least 18 years old and must have been diagnosed with childhood onset growth hormone deficiency. They should also have been registered in the BELGROW registry and finished their rhGH treatment after 2011. This trial is not yet recruiting participants, but once it starts, those who join will complete a questionnaire about their health and follow-up care. This information will help researchers understand how treatment in childhood affects health in adulthood.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age \> or = 18 years
• • Diagnosed with child-hood onset growth hormone deficiency (CO-GHD) (no exclusion criteria: isolated or multiple GHD, idiopathic or organic, severe or partial)
• • Registered in the BELGROW registry (informed consent at the time of inclusion in registry)
• • Stopped treatment with rhGH for growth after 2011
• • Persistent GHD at the end of growth
• Exclusion Criteria:
• • No exclusion criteria

Trial Officials